| scholarly article | Q13442814 |
| P2093 | author name string | Maryka Quik | |
| Danhui Zhang | |||
| Jason Ly | |||
| Archana Mallela | |||
| P2860 | cites work | The effects of nicotine on Parkinson's disease | Q28138511 |
| Invited review: the evolution of antidepressant mechanisms | Q28241221 | ||
| Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors | Q28245329 | ||
| Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation | Q28250054 | ||
| Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid | Q28278033 | ||
| Varenicline is a potent partial agonist at α6β2* nicotinic acetylcholine receptors in rat and monkey striatum | Q28576280 | ||
| Nicotinic receptor-mediated reduction in L-DOPA-induced dyskinesias may occur via desensitization | Q30475334 | ||
| Contribution of pre-synaptic mechanisms to L-DOPA-induced dyskinesia. | Q33992550 | ||
| Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial | Q33997418 | ||
| Maladaptive striatal plasticity in L-DOPA-induced dyskinesia | Q34094008 | ||
| Onset of action of antidepressants: results of different analyses | Q34156652 | ||
| Nicotine as a potential neuroprotective agent for Parkinson's disease | Q34281003 | ||
| Slow onset of CNS drugs: can changes in protein concentration account for the delay? | Q34360401 | ||
| Randomized placebo-controlled study of the nicotinic agonist SIB-1508Y in Parkinson disease | Q34494287 | ||
| 5-Iodo-A-85380, an alpha4beta2 subtype-selective ligand for nicotinic acetylcholine receptors | Q73487540 | ||
| Nicotinic receptor-mediated neuroprotection in neurodegenerative disease models | Q34954670 | ||
| Structural and functional diversity of native brain neuronal nicotinic receptors | Q34983875 | ||
| Nicotine alters limbic function in adolescent rat by a 5-HT1A receptor mechanism | Q34988469 | ||
| Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats | Q35097046 | ||
| Nicotine reduces L-DOPA-induced dyskinesias by acting at beta2* nicotinic receptors | Q35188119 | ||
| α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease | Q35264378 | ||
| Nicotine and Parkinson's disease: implications for therapy | Q35601652 | ||
| Nicotinic acetylcholine receptors and the regulation of neuronal signalling. | Q35785768 | ||
| Strategies for producing faster acting antidepressants. | Q36101382 | ||
| Guidelines on nicotine dose selection for in vivo research. | Q36560437 | ||
| Nicotinic receptor agonists as neuroprotective/neurotrophic drugs. Progress in molecular mechanisms | Q36564840 | ||
| Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation | Q36850882 | ||
| Nicotine-mediated improvement in L-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal function | Q36936920 | ||
| Neuroprotection via nAChRs: the role of nAChRs in neurodegenerative disorders such as Alzheimer's and Parkinson's disease | Q36991836 | ||
| Neurochemical pathways involved in the protective effects of nicotine and ethanol in preventing the development of Parkinson's disease: potential targets for the development of new therapeutic agents. | Q37164977 | ||
| Serotonin receptors as potential targets for modulation of nicotine use and dependence | Q37260932 | ||
| Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias | Q37260948 | ||
| Stimulating nicotinic receptors trigger multiple pathways attenuating cytotoxicity in models of Alzheimer's and Parkinson's diseases | Q37852963 | ||
| Milestones in Parkinson's disease therapeutics | Q37882596 | ||
| Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. | Q37924629 | ||
| l-Dopa-induced dyskinesia-clinical presentation, genetics, and treatment | Q37930020 | ||
| Molecular mechanisms of l-DOPA-induced dyskinesia. | Q37930022 | ||
| New approaches to therapy | Q37930023 | ||
| Emerging therapies for Parkinson's disease | Q38024685 | ||
| Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. | Q38405712 | ||
| Neuroprotection of midbrain dopamine neurons by nicotine is gated by cytoplasmic Ca2+. | Q39555649 | ||
| Ketanserin, a 5-HT2 receptor antagonist, decreases nicotine self-administration in rats | Q42829690 | ||
| Differential effects of serotonin (5-HT)2 receptor-targeting ligands on locomotor responses to nicotine-repeated treatment | Q43145206 | ||
| Transdermal nicotine in PD: a randomized, double-blind, placebo-controlled study | Q43747001 | ||
| 5-Iodo-A-85380 binds to alpha-conotoxin MII-sensitive nicotinic acetylcholine receptors (nAChRs) as well as alpha4beta2* subtypes | Q44027718 | ||
| The hyperkinetic abnormal movements scale: a tool for measuring levodopa-induced abnormal movements in squirrel monkeys | Q44165234 | ||
| Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease | Q44701012 | ||
| Effect of nicotine on the pharmacokinetics of levodopa | Q44750116 | ||
| Interactions of serotonin (5-HT)2 receptor-targeting ligands and nicotine: locomotor activity studies in rats | Q46060476 | ||
| Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease | Q46466701 | ||
| Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys | Q46932031 | ||
| Chronic high dose transdermal nicotine in Parkinson's disease: an open trial | Q46946186 | ||
| Effects of smoking in patients with early-onset Parkinson's disease | Q48252012 | ||
| Nicotine may relieve symptoms of Parkinson's disease | Q48834158 | ||
| Worsening of motor performance in patients with Parkinson's disease following transdermal nicotine administration | Q64819951 | ||
| The short-term effect of nicotine chewing gum in patients with Parkinson's disease | Q72246043 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Parkinson's disease | Q11085 |
| nicotine | Q12144 | ||
| levodopa | Q300989 | ||
| dyskinesia | Q629444 | ||
| P304 | page(s) | 1398-1406 | |
| P577 | publication date | 2013-07-08 | |
| P1433 | published in | Movement Disorders | Q1486418 |
| P1476 | title | Nicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson's disease | |
| P478 | volume | 28 |
| Q37708588 | ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease |
| Q38532889 | Alpha7 nicotinic receptors as therapeutic targets for Parkinson's disease |
| Q64868288 | Chronic nicotine improves cognitive and social impairment in mice overexpressing wild type α-synuclein |
| Q33917311 | Deficits in cholinergic neurotransmission and their clinical correlates in Parkinson's disease |
| Q47221215 | Detection of Signal Regulatory Protein α in Saimiri sciureus (Squirrel Monkey) by Anti-Human Monoclonal Antibody |
| Q38186596 | Effect of nicotine on L-dopa-induced dyskinesia in animal models of Parkinson's disease: a systematic review and meta-analysis |
| Q26764724 | Emerging preclinical pharmacological targets for Parkinson's disease |
| Q38156760 | Levodopa-induced dyskinesias in Parkinson's disease: emerging treatments |
| Q38355582 | Molecular imaging of levodopa-induced dyskinesias. |
| Q34443682 | New treatments for the motor symptoms of Parkinson's disease |
| Q33862534 | Nicotine from cigarette smoking and diet and Parkinson disease: a review. |
| Q37193201 | Nicotinic receptor agonists reduce L-DOPA-induced dyskinesias in a monkey model of Parkinson's disease |
| Q38629277 | Preclinical Evidence for a Role of the Nicotinic Cholinergic System in Parkinson's Disease |
| Q64901815 | Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson's Disease. |
| Q34112026 | Role for the nicotinic cholinergic system in movement disorders; therapeutic implications |
| Q52680310 | The striatal cholinergic system in L-dopa-induced dyskinesias. |
| Q34186299 | The α7 nicotinic receptor agonist ABT-107 decreases L-Dopa-induced dyskinesias in parkinsonian monkeys |
| Q36469995 | α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage |
Search more.